Safety and Immunogenicity of Innocell Autologous Cellular Immunotherapy for Recurrent Epithelial Ovarian Cancer

Trial Details

NCT ID

NCT06366490

Phase

PHASE1

Sponsor

PhotonPharma, Inc.

Status

RECRUITING

Cancer Type

Ovarian Cancer

Interventions

• Innocell Autologous Cellular Immunotherapy

Locations (sample)

• Duarte, California, United States|34.13945,-117.97729

Key Eligibility Criteria

• Age ≥ 18 years and female;
• Has histologically or cytologically confirmed diagnosis of advanced epithelial ovarian cancer (except carcinosarcoma), primary peritoneal, or fallo…
• Been treated with available standard-of-care therapy likely to convey clinical benefit (i.e., PARP inhibitors for women with germline BRCA mutation…
• Documented relapse or progression on or after the most recent line of therapy;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.